Posted by Michael Wonder on 20 Jul 2021
Albireo receives European marketing authorisation of Bylvay (odevixibat), the first drug treatment for progressive familial intrahepatic cholestasis
19 July 2021 - First approval in the world of Bylvay for the treatment of progressive familial intrahepatic cholestasis.
Albireo Pharma today announced European Commission authorisation of Bylvay (odevixibat), the first drug approved for the treatment of all sub-types of progressive familial intrahepatic cholestasis.
